Comprehensive precautions before taking avatinib (AYVAKIT)

Before treating gastrointestinal stromal tumors and systemic mastocytosis with avatinib (AYVAKIT), patients need to fully communicate with medical staff and inform them in detail of all personal health conditions and medication history to ensure the safety and effectiveness of treatment. The following is an in-depth analysis of the special precautions you need to take before taking avatinib.

If you have a history of swelling or weakening of blood vessel walls (aneurysms), bleeding in the brain, or a stroke within the past year, be sure to tell your healthcare provider. These situations may increase the risk during treatment, and medical personnel need to make a comprehensive assessment to formulate an appropriate treatment plan.

Patients with low platelet counts also need attention, as avatinib may affect platelet function and further aggravate bleeding tendencies. In addition, patients who have or have had liver disease should also inform medical staff in detail before treatment so that changes in liver function can be monitored and treatment plans can be adjusted in a timely manner.

For female patients, especially those of childbearing age and those who plan to become pregnant, avatinib may cause harm to the fetus. Therefore, before starting treatment, medical staff will perform a pregnancy test to make sure the patient is not pregnant. During treatment and for 6 weeks after the last dose of medication, patients should use effective contraception and consult a healthcare provider to determine the most appropriate contraceptive method. If you become pregnant unexpectedly during treatment, notify your medical provider immediately.

Male patients whose partners may become pregnant should also take contraceptive measures during treatment and within 6 weeks after the last dose of medication to protect the safety of potential fetuses.

Female patients who are breastfeeding or planning to breastfeed also need to pay special attention. It is unknown whether avatinib passes into breast milk; therefore, breastfeeding should be avoided during treatment and for at least 2 weeks after the last dose. During this time, patients should discuss the best alternatives to feeding their baby with their healthcare provider.

Patients also need to tell their health care provider about all the medications they are taking, including prescription drugs, over-the-counter drugs, vitamins, and herbal supplements. Avatinib may interact with other drugs, affecting each other's effectiveness. Especially when taking estrogen-containing hormonal contraceptives and drugs to prevent blood clots, you need to communicate with medical staff in detail to adjust the medication plan.

While taking avatinib, patients may experience confusion or difficulty thinking. At this time, patients should avoid driving or operating heavy machinery to prevent accidents. At the same time, the skin may be sensitive to sunlight or other forms of light. Exposure to direct sunlight, sunlamps and other ultraviolet radiation sources should be avoided or limited during treatment and within one week after stopping the drug. When outside, you should protect your skin by using sunscreen or wearing clothing that covers your skin.

Finally, if a patient experiences certain side effects, health care providers may adjust the dose of avatinib or temporarily or permanently stop treatment. Patients need to pay close attention to their own reactions and communicate with medical staff in a timely manner to ensure the safety and effectiveness of treatment.

In summary, comprehensive considerations and precautions before taking avatinib are crucial to ensure the safety and effectiveness of the treatment. Patients should fully communicate with medical staff, inform them in detail of their personal health status and medication history, and jointly develop an appropriate treatment plan.

Reference materials:https://www.drugs.com/pro/ayvakit.html